A5054829636- Pharmacogenetics and Drug Metabolism
- Hormonal Regulation and Hypertension
- Pharmaceutical studies and practices
- Cancer Genomics and Diagnostics
- Attention Deficit Hyperactivity Disorder
- Statistical Methods in Clinical Trials
- Eicosanoids and Hypertension Pharmacology
- Computational Drug Discovery Methods
- Drug Transport and Resistance Mechanisms
- Bipolar Disorder and Treatment
- Forensic Toxicology and Drug Analysis
- Molecular Biology Techniques and Applications
- Estrogen and related hormone effects
- Biosimilars and Bioanalytical Methods
- Receptor Mechanisms and Signaling
- Neurotransmitter Receptor Influence on Behavior
- Lung Cancer Treatments and Mutations
- Autism Spectrum Disorder Research
- Genetics and Neurodevelopmental Disorders
- Extracellular vesicles in disease
- Drug-Induced Hepatotoxicity and Protection
- Genomics, phytochemicals, and oxidative stress
- Tea Polyphenols and Effects
- Glutathione Transferases and Polymorphisms
- Metabolomics and Mass Spectrometry Studies
University of Louisville
2013-2024
James Graham Brown Foundation
2024
Azienda Ospedaliera di Padova
2021
University of Padua
2021
Walter de Gruyter (Germany)
2021
University of Louisville Hospital
2012-2020
Max Planck Institute of Biophysics
2016-2020
Syracuse University
2002-2010
Kinderklinik Regensburg
2002-2005
Summary Cytochrome P-450 2C9 (CYP2C9) polymorphisms (CYP2C9*2 and CYP2C9*3) reduce the clearance of warfarin, increase risk bleeding, prolong time to stable dosing. Whether prospective use a retrospectively developed algorithm that incorporates CYP2C9 genotype nongenetic factors can ameliorate propensity bleeding delay in achieving warfarin dose is unknown. We initiated therapy 48 orthopedic patients tailored following variables: genotype, age, weight, height, gender, race, simvastatin or...
Abstract Background: CYP2C9 polymorphisms are associated with decreased S-warfarin clearance and lower maintenance dosage. Decreased expression of VKORC1 resulting from the −1639G>A substitution has also been implicated in warfarin dose requirements. We investigated additional contribution this polymorphism to variance dose. Methods: Sixty-five patients stable anticoagulation were genotyped for Tag-It™ allele-specific primer extension technology. Plasma concentrations compared among...
Polymorphism in the genes for cytochrome (CYP)2C9 and vitamin K epoxide reductase complex subunit 1 (VKORC1) affect pharmacokinetics pharmacodynamics of warfarin. We developed validated a warfarin-dosing algorithm multi-ethnic population that predicts best dose stable anticoagulation, compared its performance against other regression equations.We determined allele haplotype frequencies CYP2C9 VKORC1 on 167 Caucasian, African-American, Asian Hispanic patients On subset where complete data...
Abstract Several lines of evidence indicate an involvement brain derived neurotrophic factor (BDNF) in body weight regulation and activity: heterozygous Bdnf knockout mice ( +/− ) are hyperphagic, obese, hyperactive; furthermore, central infusion BDNF leads to severe, dose‐dependent appetite suppression loss rats. We searched for the role variants obesity, eating disorders, attention‐deficit/hyperactivity disorder (ADHD). A mutation screen (SSCP DHPLC) translated region 183 extremely obese...
Abstract Pharmacogenetics is the study of linkage between an individual’s genotype and that ability to metabolize a foreign compound. Differences in metabolism therapeutics can lead severe toxicity or therapeutic failure by altering relation dose blood concentration pharmacologically active drug. Phenotypes exhibiting poor ultraextensive result from genetic variance (polymorphism) enzymes involved metabolism. Thus, pharmacogenetic studies one applies genotyping polymorphic alleles encoding...
Radiographic imaging is the current standard for monitoring progression of tumor-burden and therapeutic resistance in patients with metastatic melanoma. Plasma circulating tumor DNA (ctDNA) has shown promise as a survelience tool, but longitudinal data on dynamics between plasma ctDNA concentrations radiographic lacking. We evaluated relationship measures burden 30 melanoma systemic treatment. In 9 no evidence disease over total 15 time points, were undetectable. 21 burden, was detected 81 %...
Warfarin is the most commonly prescribed oral anticoagulant for treatment and prevention of thromboembolic events. The correct maintenance dose warfarin a given patient difficult to predict, drug carries high risk toxicity, variability among patients means that safe range differs widely between individuals. Recent pharmacogenetic studies indicate routine incorporation genetic testing into therapy protocols could substantially ease both financial health risks currently associated with this...
The application of pharmacogenetic results requires demonstrable correlations between a test result and an indicated specific course action. We developed computational decision-support tool that combines patient-specific genotype phenotype information to provide strategic dosage guidance. This tool, through estimating quantitative temporal parameters associated with the metabolism- concentration-dependent response warfarin, provides necessary context for interpreting international normalized...
Summary We performed a randomised pilot trial of PerMIT, novel decision support tool for genotype-based warfarin initiation and maintenance dosing, to assess its efficacy improving management. prospectively studied 26 subjects compare PerMIT-guided management with routine anticoagulation service CYP2C9 VKORC1 genotype results 13 randomly assigned the PerMIT arm were recorded within 24 hours enrolment. To aid in INR interpretation, calculates estimated loading doses based on patient’s genetic...